Diet soda linked to increase in glucagon-like peptide 1 levels

Diet soda linked to increase in glucagon-like peptide 1 levels
Drinking a diet soda before a glucose load is associated with increased glucagon-like peptide 1 secretion in individuals with type 1 diabetes and healthy controls, but not in those with type 2 diabetes, according to research published online March 12 in Diabetes Care.

(HealthDay) -- Drinking a diet soda before a glucose load is associated with increased glucagon-like peptide 1 (GLP-1) secretion in individuals with type 1 diabetes and healthy controls, but not in those with type 2 diabetes, according to research published online March 12 in Diabetes Care.

Rebecca J. Brown, M.D., M.H.S.C., of the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Md., and colleagues conducted a randomized, crossover study involving nine individuals with type 1 diabetes, 10 with type 2 diabetes, and 25 healthy controls, aged 12 to 25 years. Participants drank either a cola-flavored, caffeine-free or carbonated water, followed by a 75-gram glucose load. They then underwent glucose, C-peptide, GLP-1, glucose-dependent insulinotropic peptide, and peptide Tyr-Tyr measurements for 180 minutes.

Compared with carbonated water, the researchers found that, after ingestion of diet soda, the GLP-1 area under the curve was 34 percent higher in healthy subjects and 43 percent higher in individuals with (P = 0.029 and 0.020, respectively), but was unaffected in subjects with type 2 diabetes. None of the other gut hormone measures were significantly statistically different between the groups after ingestion of diet soda or carbonated water.

"It is unknown whether changes in endogenous GLP-1 secretion as observed in the current study have any clinically relevant consequences, such as increased satiety and slowed gastric emptying," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Bile acids may hold clue to treat heart disease

Dec 06, 2011

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation. The ...

A new molecule to combat diabetes and obesity

Sep 01, 2009

Type 2 diabetes, the most common form of diabetes, is increasing at an alarming state with more than 180 million people affected worldwide. With the rising incidence of obesity, a major risk factor for the onset of type 2 ...

Improving psoriasis with GLP-1 analogue therapy

Dec 13, 2011

(Medical Xpress) -- UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following ...

Recommended for you

Added fructose is a principal driver of type 2 diabetes

Jan 29, 2015

Recent studies have shown that added sugars, particularly those containing fructose, are a principal driver of diabetes and pre-diabetes, even more so than other carbohydrates. Clinical experts writing in Mayo Clinic Proceedings challe ...

Support found for peer-mentoring diabetes management program

Jan 29, 2015

Managing type 1 diabetes is a never-ending task that requires multiple blood glucose tests, carbohydrate calculations and insulin injections or infusions. This constant effort to control the disease is daunting at any age ...

How does DPP-4 inhibition affect liver function?

Jan 27, 2015

(HealthDay)—Dipeptidyl peptidase-4 (DPP-4) inhibition may attenuate hepatic steatosis and insulin resistance induced by the Western diet (WD) through hepatic lipid remodeling and modulation of hepatic mitochondrial ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.